AI assistant

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Salarius Pharmaceuticals, Inc. Director's Dealing 2023

Jan 6, 2023

35494_dirs_2023-01-05_5191fa83-d478-4175-b883-db785c7a269c.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Salarius Pharmaceuticals, Inc. (SLRX)
CIK: 0001615219
Period of Report: 2023-01-03

Reporting Person: HANISH ARNOLD C (Director)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2023-01-03	Common Stock	A	1440	—	Acquired	1440	Direct

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock	1854	Indirect

Footnotes

F1: Restricted stock granted under the Salarius Pharmaceuticals, Inc.2015 Equity Incentive Plan. 100% of the restricted stock will vest on January 2, 2024